SUMMARY OF PRODUCT CHARACTERISTICS. Medical conditions that require parenteral nutrition for supply of energy and essential fatty acids.
|
|
- Marshall Warren
- 5 years ago
- Views:
Transcription
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alphalipid 200 mg/ml emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000 ml of the emulsion contain: Soya-bean oil, refined Energy content: 200 g 2000 kcal/l (8.4 MJ/l) Excipient with known effect: Sodium 0.03 mg/ml (see section 4.4) For the full list of excipients, see section PHARMACEUTICAL FORM Alphalipid is a milky white emulsion for infusion. Osmolality: about 350 mosm/kg water ph: CLINICAL PARTICULARS 4.1 Therapeutic indications Medical conditions that require parenteral nutrition for supply of energy and essential fatty acids. 4.2 Posology and method of administration Posology Adults The patient s ability to eliminate the infused fat should determine the dosage (see Treatment monitoring below). The quantity of fat administered intravenously should normally not exceed 3 g/kg bodyweight/day. The highest permitted infusion rate is 1.6 ml/min, equivalent to an infusion time of at least 5 hours for 500 ml. Paediatric population The child s ability to eliminate fat should determine the dosage (see Treatment monitoring below). The recommended daily dose is g fat/kg bodyweight. The infusion rate should not exceed 0.17 g fat/kg bodyweight/hour (4 g fat/kg per 24 hours). In premature and very low birth weight infants Alphalipid should preferably be administered continuously over 24 hours. The initial dosage should be g fat/kg bodyweight/day. The dose should then be increased gradually by g fat/kg Page 1
2 bodyweight/day up to 2 g fat/kg bodyweight/day. The dosage may be increased to 4 g/kg/day only under close monitoring of serum triglyceride concentrations, liver function and oxygen saturation. Method of administration Alphalipid should be administered as an intravenous infusion. Treatment monitoring Adults: where intravenous fat emulsion is indicated for more than a week, the patient s ability to eliminate fat should be checked. A sample of blood should be taken before the start of the infusion and centrifuged. If the plasma is milky or opalescent, the planned infusion should be postponed. Be aware that hypertriglyceridaemia may pass undetected with this method. In patients in whom impaired fat tolerance may be expected, measurement of the serum triglyceride concentration is therefore recommended. The elimination of fat should be checked daily in the medical conditions mentioned in section 4.4. Paediatric population: in infants treated with Alphalipid the ability to eliminate fat should be tested regularly. In infants receiving long-term parenteral nutrition, particularly premature infants, platelet count, liver function and serum triglycerides should be monitored daily. Specific measurement of the serum triglyceride concentration is recommended for this group. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypersensitivity to egg protein. Hypersensitivity to soya-bean protein or peanut protein. Alphalipid contains soya-bean oil. Cross-allergy occurs between peanuts and soya-beans. Acute shock. Conditions involving severe hyperlipidaemia. Severe hepatic failure. Haemophagocytic syndrome. 4.4 Special warnings and precautions for use Caution should be observed in conditions with impaired fat metabolism, such as renal impairment, uncontrolled diabetes, pancreatitis, hepatic impairment, hypothyroidism (if hypertriglyceridaemia is present) and sepsis. If Alphalipid is given in these conditions, the serum triglyceride concentration should be monitored closely. Paediatric population Alphalipid should be given with caution to neonates and premature infants with hyperbilirubinaemia and in cases of suspected pulmonary hypertension. Interference with serological testing Alphalipid may interfere with certain laboratory tests (bilirubin, lactate dehydrogenase, oxygen saturation, Hb, etc.) if blood is sampled before the administered fat has been cleared from the blood. In most patients fat is cleared from the blood 5-6 hours after the end of the infusion. This medicinal product contains 0,65 mmol sodium (15 mg) per 500 ml, i.e. essentially sodium- free. Page 2
3 4.5 Interaction with other medicinal products and other forms of interaction Certain medicinal products such as insulin can affect the body s lipase system. This type of interaction, however, is considered to be of limited clinical significance. Heparin in clinical doses causes a transient increase in lipolysis in plasma, resulting in a transient decrease in triglyceride clearance due to depletion of lipoprotein lipase. Soya-bean oil has a natural content of vitamin K 1. This is considered important only in patients treated with coumarin derivatives, which interact with vitamin K Fertility, pregnancy and lactation Pregnancy Data on a limited number of exposed pregnancies indicate no adverse effects of Alphalipid on pregnancy or on the health of the fetus/newborn child. To date, no other relevant epidemiological data are available. Caution should be exercised when prescribing to pregnant women. Breastfeeding There is insufficient information on the excretion of soya-bean oil in human milk. Fertility There is insufficient information on the effect on fertility. 4.7 Effects on ability to drive and use machines Alphalipid has no or negligible influence on the ability to drive and use machines. 4.8 Undesirable effects The following frequencies are taken as a basis when evaluating undesirable effects: Very common: 1/10 Common: 1/100 to <1/10 Uncommon: 1/1000 to <1/100 Rare: 1/10,000 to <1/1,000 Very rare: <1/10,000 Not known: cannot be estimated from the available data Following undesirable effects were reported for the reference soya-bean emulsion for infusion: System organ class Frequency Event Blood and lymphatic system disorders Rare Haemolysis, reticulocytosis, thrombocytopenia (in association with long-term treatment in infants) Vascular disorders Rare Hypertension, hypotension Respiratory, thoracic and mediastinal disorders Rare Tachypnoea Hepatobiliary disorders Rare Hepatic impairment Page 3
4 System organ class Frequency Event Skin and subcutaneous tissue disorders Uncommon Flushing Rare Skin rash, urticaria Reproductive system and breast disorders Rare Priapism General disorders and administration site conditions Uncommon Rare Fever, chills, nausea Anaphylactic reaction, headache, abdominal pain, tiredness The rare side effects can occur during or following infusion (early effects) or after extended treatment. Early effects that occur at the recommended dose include allergic reactions, abdominal pain, haemolysis, headache, hypertension, hypotension, priapism, reticulocytosis, tachypnoea and tiredness. Effects reported in long-term treatment include thrombocytopenia in infants. Fat overload syndrome An impaired ability of the patient to eliminate Alphalipid can lead to fat overload syndrome, which may be caused by overdose. This syndrome may appear during severe hypertriglyceridaemia, even at the recommended infusion rate, and in association with a sudden change in the patient s clinical condition, such as renal function impairment or infection. Fat overload syndrome is characterised by hyperlipidaemia, fever, fat infiltration, hepatomegaly, splenomegaly, anaemia, leukopenia, thrombocytopenia, coagulation disorder and coma. The symptoms are usually reversible if the treatment is discontinued. Transient changes in liver function have been noted in association with intravenous nutrition, but the cause is unknown. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system listed in Appendix V*. 4.9 Overdose See section 4.8 under Fat overload syndrome. A marked overdose of fat emulsions containing triglycerides can result in metabolic acidosis, particularly if carbohydrates are not given concomitantly. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions, ATC code: B05BA02. Alphalipid is a fat emulsion for intravenous use containing soya-bean oil emulsified with egg phospholipids. Particle size and biological properties are similar to those of natural chylomicrons. Unlike chylomicrons, Alphalipid does not contain cholesterol esters or apolipoproteins, while its phospholipid content is significantly higher. Page 4
5 5.2 Pharmacokinetic properties The fat particles in Alphalipid are in principle distributed and eliminated in the same way as natural chylomicrons. 5.3 Preclinical safety data Refined soya-bean oil emulsion for infusion has been used clinically for many years. Its safety is based on clinical experience. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients purified egg yolk phospholipids glycerol sodium oleate sodium hydroxide water for injections 6.2 Incompatibilities This medicinal product must not be mixed with other medicinal products except those mentioned in section Shelf life Shelf life in the unopened bottle: 2 years Shelf life in the opened container: Because of the risk of microbial contamination the product should be used immediately. Any unused infusion should be discarded. Shelf life after compounding: Chemical and physical in-use stability has been demonstrated for 4 weeks at 25 C under light protection. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 C, unless compounding has taken place in controlled and validated aseptic conditions. Do not freeze the compounded emulsion. 6.4 Special precautions for storage Do not freeze. For storage conditions after compounding, see section 6.3. Page 5
6 6.5 Nature and contents of container Type II glass bottle with 100 ml, 250 ml or 500 ml infusion, closed with a chlorobutyl rubber stopper sealed with an aluminium capsule. Pack sizes: Glass bottle: 20 x 100 ml 20 x 250 ml 10 x 500 ml Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling Do not use the product if the package is damaged. Do not use if you notice phase separation of the emulsion. Compounding Alphalipid may be compounded with medicinal products containing amino acids, glucose and electrolyte solutions under aseptic conditions to produce Intradialytic Parenteral Nutrition (IDPN) and Total Parenteral Nutrition (TPN) admixtures. Medicinal products with the volume of 5 ml and more should be mixed with Alphalipid at once, using an automatic filling system. Volumes below 5 ml may be added separately to the pre-mixture. These processes should be executed under aseptic conditions (see section 6.3). The table below shows the highest concentration of components for which the chemical and physical stability has been demonstrated (see section 6.3): Components Soya-bean oil [g] (source: Alphalipid) Composition for Intradialytic Parenteral Nutrition per 100 ml Composition for Total Parenteral Nutrition per 100 ml Amino acids [g] Glucose [g] Overall omega 3-fatty acids [g] max max Omega 3-fatty acids from fish oil [g] (source: Omegaven) Omega 3-fatty acids from soya-bean oil [g] (source: Alphalipid) max max max max Electrolytes 0 Sodium [mmol] Page 6
7 Calcium [mmol] Magnesium [mmol] Zinc [µmol] Potassium [mmol] Chloride [mmol] Phosphate [mmol] Acetate [mmol] Citrate [mmol] Malate [mmol] Saccharate [mmol] Gluconate [mmol] Water for injections can be used to adjust the target concentrations of the corresponding components. 7. MARKETING AUTHORISATION HOLDER ALPHA PHARMACEUTICALS GmbH Hauptstraße 61 A D Wandlitz Germany 8. MARKETING AUTHORISATION NUMBER 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 10. DATE OF REVISION OF THE TEXT Page 7
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Kombilipid 200 mg/ml emulsion for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1000 ml of emulsion for infusion contain: Soya-bean
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Addaven concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Addaven contains: 1 ml 1 ampoule (10 ml) Chromic
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albuman 40 g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albuman 40 g/l is a solution containing 40 g/l (4%)
More informationAminosteril N-Hepa 8%, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Title Page Information Aminosteril N-Hepa 8% November 2001 1 (7) 1. NAME OF THE MEDICINAL PRODUCT Aminosteril N-Hepa 8%, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000 ml solution
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Albunorm 5%, 50 g/l, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 5% is a solution containing 50 g/l of total
More informationPRODUCT INFORMATION. NAME OF MEDICINE INTRALIPID 10%, 20% and 30% (Sterile fat emulsions containing soya oil, egg lecithin and glycerol).
PRODUCT INFORMATION NAME OF MEDICINE INTRALIPID 10%, 20% and 30% (Sterile fat emulsions containing soya oil, egg lecithin and glycerol). The active ingredient is Soya Oil (CAS No.: 8001-22-7). DESCRIPTION
More informationSUMMARY OF PRODUCT CHARACTERISTICS mg (6.85 mg)
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Aminoplasmal B. Braun 10% E Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The solution for infusion contains: per
More informationProtamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion.
1. NAME OF THE MEDICINAL PRODUCT Protamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Protamine sulphate 1400 anti-heparin
More information1. NAME OF THE MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Kabiven Peripheral emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Kabiven Peripheral is available in a three chamber
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alburex 5, 50 g/l, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Alburex 5 is a solution containing 50 g/l of total
More information3. PHARMACEUTICAL FORM Solution for infusion. A clear, slightly viscous liquid; it is almost colourless, yellow, amber or green.
1. NAME OF THE MEDICINAL PRODUCT Albutein 250 g/l, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human albumin Albutein 250 g/l is a solution containing 250 g/l of total protein of
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Albunorm 20%, 200 g/l, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 20% is a solution containing 200 g/l
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Lipoplus 200 mg/ml emulsion for infusion SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000 ml of emulsion contains: Medium-chain triglycerides
More informationHuman Albumin 200 g/l Baxter is a solution containing 200 g/l of total protein of which at least 95% is human albumin.
1. NAME OF THE MEDICINAL PRODUCT Human Albumin 200 g/l Baxter Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human Albumin 200 g/l Baxter is a solution containing 200 g/l of total protein
More information1.3.1 SPC, Labelling and Package Leaflet (Voluven Fresenius 6% Solution for Infusion)
1.3.1 SPC, Labelling and Package Leaflet (Voluven Fresenius 6% Solution for Infusion) 1.3.1 SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albunorm 20%, 200g/l, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 20% is a solution containing 200 g/l
More information(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS
albunorm TM 5% (human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS UK IRELAND and Ireland Octapharma Limited The Zenith Building, 26 Spring Gardens Manchester M2 1AB United Kingdom 1. Name
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Flexbumin 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flexbumin 200g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Flexbumin 200 g/l is a solution containing 200 g/l
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Synthamin 14, 8.5% Amino Acid Intravenous Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION L-Leucine Ph. Eur 0.620% w/v L-Isoleucine
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SimAlvia 60 mg/300 mg, soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each soft capsule contains 60 mg alverine citrate and
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each ml of solution for infusion contains 10 mg of paracetamol.
Module 1.3.1 SPC, Labelling and Package Leaflet Page 1/8 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Paracetamol Rompharm 10 mg/ml solution for infusion 2. QUALITATIVE AND QUANTITATIVE
More information(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS
albunorm TM 20% (human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS UK IRELAND and Ireland Octapharma Limited The Zenith Building, 26 Spring Gardens Manchester M2 1AB United Kingdom 1. Name
More informationVamin 18 EF QUALITATIVE AND QUANTITATIVE COMPOSITION
Title Page Information Dec. 2000 1 (7) Number Vamin 18 EF 121-01 1. NAME OF THE MEDICINAL PRODUCT Vamin 18 g N/l electrolyte-free infusion fluid, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GAMMANORM, 165 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg) Human
More informationOlive oil, Soybean oil
CLINOLEIC 20% Olive oil, Soybean oil Composition Refined olive oil and refined soys bean oil*... Corresponding to a content of essential fatty acids... 20.00 g 4.00 g Per 100 ml *Mixture of refined olive
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT PRIMENE 10% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each litre of the infusion solution contains: L-Isoleucine L-Leucine L-Valine
More informationSUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 25 000 IU Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION A 2.5ml single-dose bottle containing 25 000 IU Cholecalciferol
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Lipoplus 200 mg/ml emulsion for infusion Medium-chain triglycerides / soya-bean oil, refined / omega-3-acid triglycerides Read all of this leaflet carefully
More informationAPPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS
SmPC Country: Lebanon Date of approval : 17/08/2011 Procedure : National APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1- NAME OF THE MEDICINAL PRODUCT DECAN, concentrate for solution for infusion 2- QUALITATIVE
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME ADDAVEN (infusion, solution concentrate) NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 ml ampoule of Addaven contains: Chromic chloride hexahydrate 53.33 µg
More informationFasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.
1. NAME OF THE MEDICINAL PRODUCT Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 ml of Fasturtec concentrate
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS ----------------------------------------------------------------------------------------------------------------- 1. NAME OF THE MEDICINAL PRODUCT Legalon SIL 528.5 mg
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm Junior, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of contains the following active
More informationCOMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)
COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH) HUMAN ALBUMIN 20 % BEHRING Rev.: 05-MAR-2008 / PEI approval 26.02.08 Supersedes previous versions Rev.: 28-NOV-2007 / Adaptation to Core SPC Rev.: 02-JAN-2007
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each ml solution for injection contains phenylephrine hydrochloride corresponding to 0.1 mg phenylephrine.
1. NAME OF THE MEDICINAL PRODUCT Fenylefrin Abcur 0.05 mg/ml, solution for injection Fenylefrin Abcur 0.1 mg/ml, solution for injection SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zaditen 0.25 mg/ml, eye drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains 0.345 mg ketotifen fumarate corresponding
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT WICK Chesty Cough Syrup 200 mg/15 ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 15 ml syrup contains 200 mg guaifenesin. Each ml syrup
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,
More informationRasburicase 1.5 mg/ml powder and solvent for concentrate for solution for infusion. FASTURTEC
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory This package insert is continually updated. Please read carefully before using a new pack. Rasburicase 1.5 mg/ml powder
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Human proteins g/l g/l of which human immunoglobulin at least to. 180 IU/ml 180 IU/vial
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT UMAN BIG 180 IU/ml Solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. UMAN BIG 180 IU/1
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Omnilax 10 g powder for oral solution, sachet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 10 g of macrogol 4000.
More informationPackage leaflet: Information for the user. Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion
Package leaflet: Information for the user Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion Read all of this leaflet carefully before you start using
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Calcium Sandoz 500 mg, effervescent tablets Calcium Sandoz 1000 mg, effervescent tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More information2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY 3. COMPOSITION OF THE MEDICINAL PRODUCT
Title Page Product Information May 2000 1 (6) Product Nephrotect 1. NAME OF THE MEDICINAL PRODUCT Nephrotect 2. PRESCRIPTION STATUS/RESTRICTION OF SALES TO PHARMACIES ONLY For sale in pharmacies only 3.
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Refined olive oil and refined soybean oil* 20.00g corresponding to a content of essential fatty acids 4.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT ClinOleic 20% 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition per 100 ml Refined olive oil and refined soybean oil* 20.00g corresponding
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT TRANSISOFT 8.5 g powder for oral solution in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains 8.5 g of macrogol
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients:
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Macrovic Junior powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution
More informationPackage leaflet: Information for the user. SmofKabiven emulsion for infusion
Package leaflet: Information for the user SmofKabiven emulsion for infusion Read all of this leaflet carefully before you start using this medicine because it contains important information for you. -
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fibrogammin 250 IU Powder and solvent for solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More information- Risk Management Plan - Nutriflex Omega plus-special-eu
Date: 2015-07-24 Page: 108 of 201 VI.2. Elements for a Public Summary VI.2.1. Overview of disease epidemiology Patients may need parenteral nutrition (PN) for any variety of diseases or conditions that
More information100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hedussin syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L.,
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT DigiFab (referred to as DIGIFAB) 40 mg/vial digoxin immune Fab, Powder for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 10 000 IU/ml Oral Drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml oral solution contains: 10 000 IU Cholecalciferol
More informationPackage leaflet: Information for the user. Nutriflex Omega plus Emulsion for infusion
Package leaflet: Information for the user Nutriflex Omega plus Emulsion for infusion Read all of this leaflet carefully before you start using this medicine because it contains important information for
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT ALVERINE Mayoly Spindler, 60 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 60 mg of alverine citrate.
More informationFor the use of a registered medical practitioner or a Hospital or a Laboratory only
For the use of a registered medical practitioner or a Hospital or a Laboratory only Intravenous Fat Emulsion NIRPID * Intravenous fat Emulsion DESCRIPTION: NIRPID * is a stable fat emulsion prepared from
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Human Medicines Evaluation Unit London, 27 April 2006 CPMP/BPWG/4027/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CORE SPC FOR HUMAN PLASMA DERIVED
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Citanest with Octapressin Dental 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Prilocaine Hydrochloride 30 mg (54 mg/1.8
More informationHuman plasma protein 50 mg/ml of which at least 96% is IgG, with a content of antibodies to Hepatitis B virus surface antigen (HBs) of 50 IU/ml
Hepatect CP 1. NAME OF THE MEDICINAL PRODUCT Hepatect CP 50 IU/ml; solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human hepatitis B immunoglobulin. Human plasma protein 50 mg/ml of which
More informationACETYLCYSTEINE INJECTION
ACETYLCYSTEINE INJECTION 1. Name of the medicinal product Acetylcysteine 200 mg/ml Injection 2. Qualitative and quantitative composition Acetylcysteine 200mg per ml (as N-acetylcysteine) Each 10ml ampoule
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Otrivin Menthol (without preservative) 1.0 mg/ml nasal spray, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 1.0 mg
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Compound Macrogol 13.72 g powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Compound Macrogol 13.72 g
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DigiFab, 40 mg/vial digoxin immune Fab, Powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each glass vial
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution.
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Molaxole powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains following active substances Macrogol
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DUPHALYTE Solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Composition per ml VITAMINS
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flavamed Hustensaft 15 mg/5 ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of oral solution contains 3 mg ambroxol
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationOrgalutran 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 1. NAME OF THE MEDICINAL PRODUCT 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 0.25 mg of ganirelix (INN) in 0.5 mg aqueous solution.
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Paracetamol 80mg Suppositories 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 80mg Paracetamol For a full list of
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Diclofenac Orifarm, 11.6 mg/g gel. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 gram Diclofenac Orifarm gel contains 11.6 mg (1.16%)
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT SmofKabiven extra Nitrogen Electrolyte free, emulsion for infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT SmofKabiven extra Nitrogen Electrolyte free, emulsion for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION SmofKabiven extra Nitrogen
More informationNEW ZEALAND DATA SHEET
1 PRODUCT NAME MINIRIN 0.1mg/mL nasal drops MINIRIN 0.1mg/mL Nasal Drops Desmopressin acetate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1mL contains 0.1mg desmopressin acetate which corresponds to
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mucodyne 250 mg/5 ml Syrup 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml of oral solution contains 250 mg of Carbocisteine. Also
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ketosteril film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: (RS)-3-methyl-2-oxovaleric
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Prostasan soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 320 mg of extract (as soft extract) from Serenoa
More information[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PROPOSED PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Uniferon 200 mg/ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN FOR SUBCUTANEOUS AND INTRAMUSCULAR USE (CPMP/BPWG/282/00)
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN NORMAL IMMUNOGLOBULIN
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Procto-Glyvenol, 400 mg + 40 mg, suppository Procto-Glyvenol, 5% + 2%, rectal cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One suppository
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT STRIVIT-D3 3,200 IU Capsules, Soft 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 3,200 IU Colecalciferol (equivalent
More informationWHO PACKAGE INSERT. GlaxoSmithKline Biologicals FluLaval. Dossier First - Chapter 1 to 10 for WHO
77 WHO PACKAGE INSERT 11 Chapter 4_Annex 4.4-1_ WHO leaflet_en - Page 1 78 1. NAME OF THE MEDICINAL PRODUCT, suspension for injection Influenza vaccine (split virion, inactivated) 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lidokain Isdin 40 mg/g cream 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 g cream contains 40 mg lidocaine. Excipients: Propylene glycol
More informationThis vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccinations.
NAME OF THE MEDICINAL PRODUCT IMOVAX POLIO, suspension for injection in a prefilled syringe or multidose Poliomyelitis vaccine (inactivated) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml)
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Magnesium Trisilicate Mixture B.P. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Magnesium Trisilicate B.P. 250 mg/5 ml Light Magnesium
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT STRIVIT-D3 20,000 IU Capsules, Soft 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 20,000 IU Colecalciferol (equivalent
More informationProduktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes.
Produktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes. Informationen kommer inte att uppdateras eftersom läkemedlet
More informationGuideline on core SmPC for human albumin solution (EMA/CHMP/BPWP/494462/2011/Rev.3)
26 July 2018 EMA/CHMP/BPWP/494462/2011 rev.3 Committee for Medicinal Products for Human Use (CHMP) (EMA/CHMP/BPWP/494462/2011/Rev.3) Adopted by CHMP for release for consultation 21 June 2012 Start of public
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Fucidin 20mg/g Cream Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of cream contains 20mg fusidic acid. Excipients with known effect:
More informationVALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics
Sandoz Business use only Page 1 of 5 Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Valeriaan Sandoz omhulde tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains
More informationNEW ZEALAND DATA SHEET. SMOFlipid emulsion for infusion is a white homogenous emulsion. Each 1000 ml contains:
1. PRODUCT NAME NEW ZEALAND DATA SHEET SMOFlipid 20% emulsion for infusion Pack sizes SMOFlipid 20% is available in pack sizes of: 10 x 100mL 10 x 250mL 12 x 500mL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Tipol 75mg Suppositories Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 75mg of paracetamol For a full list of excipients,
More informationExcipients with known effect: Each gramme of gel contains 1 mg methyl parahydroxybenzoate (E-218) and 0.5 mg propyl parahydroxybenzoate (E-216).
VENOSMIL 1. NAME OF THE MEDICINAL PRODUCT VENOSMIL 200 mg hard capsules VENOSMIL 20 mg/g gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION VENOSMIL 200 mg hard capsules Each capsule contains 200 mg hidrosmin.
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Panadol Baby 120 mg/5 ml, Oral Suspension. Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml spoonful of suspension contains paracetamol
More information